Background from APHA:
“The U.S. Senate is considering two separate bills that would create a new requirement for mandatory product listing (MPL) for all dietary supplements marketed in the United States. One of these is found in section 811 of S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDASLA), which will be the focus of a markup in the Senate Health, Education, Labor, and Pensions (HELP) Committee this coming week on June 8, 2022.
The other is standalone legislation recently introduced by Senator Durbin (D-IL) and Senator Braun (R-IN), S. 4090. ”
|
|